Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis NYT | Top Stories Rebecca Robbins 23 September 2025 at 04:10 Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting a public-relations nightmare as President Trump and others suggest unproven links between the pain reliever and autism. © Brendan McDermid/ReutersKenvue, a spinoff of Johnson & Johnson, debuted at the New York Stock Exchange in 2023.
Where U.S. Medicines Are Made and How Trump’s Tariffs Could Affect Them NYT | China Rebecca Robbins and Jonathan Corum 24 August 2025 at 11:39 President Trump’s planned pharmaceutical tariffs threaten to hit many of the most common and well-known drugs that Americans take.
Login
